Status: Recruiting
Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy
The main purpose of this study is to evaluate the efficacy of MY008211A compared to eculizumab in PNH patients.
Participants needed: 66
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Wuhan Createrna Science and Technology Co., LtdUpdated: May 9, 2025Locations: 2
Eligibility criteria
Male and female participants ≥ 18 years of age and BMI ≥ 18.0 kg/m2 with a diagn... [+3]
Patients with reticulocytes <100x10^9/L; platelets <30x10^9/L; neutrophils <0.5x... [+5]